ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Spondyloarthropathies"

  • Abstract Number: 0406 • ACR Convergence 2022

    Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?

    Sinead Maguire1, Fiona Wilson2, Phil Gallagher3 and Finbar (Barry) O'Shea1, 1St James' Hospital, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3St Vincent's University Hospital, Dublin, Ireland

    Background/Purpose: The tools to assess disease activity and quality of life in axial spondyloarthritis (axSpA) were developed in ankylosing spondylitis cohorts biased towards inclusion of…
  • Abstract Number: 1032 • ACR Convergence 2022

    Anti-arthritogenic Effect of Smoking in Curdlan-Administered SKG Mice

    YoungEun Kim1, Eun-Ju Lee1, Jae-Hyun Lee1, Soo Min Ahn1, Ji Seon Oh2, Seokchan Hong1, Chang Keun Lee1, Bin Yoo1 and Yong Gil Kim1, 1Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 2Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea

    Background/Purpose: Alpha7 nicotinic acetylcholine receptor (α7nAChR), a member of AChR expressed in various immune cells and synoviocytes, has an important role in the anti-inflammatory pathway…
  • Abstract Number: 1601 • ACR Convergence 2022

    Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial

    Michaela Koehm1, Ann Christina Foldenauer2, Tanja Rossmanith3, Herbert Kellner4, Uta Kiltz5, Juergen Rech6, Gerd Burmester7, David Kofler8, Jan Brandt-Juergens9, Stephanie Finzel10, Raoul Bergner11, Maren Sieburg12 and Frank Behrens13, 1Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, 2Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, 3Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, Germany, 4Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany, 6University Clinic Erlangen, Erlangen, Germany, 7Charité University Medicine Berlin, Berlin, Germany, 8University of Cologne, Cologne, Germany, 9Rheumatologische Schwerpunktpraxis, Berlin, Germany, 10University of Freiburg, Freiburg, Germany, 11Klinikum Ludwigshafen, Ludwigshafen, Germany, 12Rheumatologische Facharztpraxis, Magdeburg, Germany, 13Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany

    Background/Purpose: Subgroup analysis from different clinical trials and real-world data suggest, that there are differences in baseline characteristics, clinical phenotypes, and treatment responses in female…
  • Abstract Number: 0413 • ACR Convergence 2022

    Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis

    Augusta Ortolan1, Casper Webers2, Alexandre Sepriano3, Louise Falzon4, Xenofon Baraliakos5, Robert Landewé6, Sofia Ramiro7, Désirée van der Heijde8 and Elena Nikiphorou9, 1University of Padova/Leiden University Medical Center, Padova, Italy, 2Maastricht University Medical Centre, Maastricht, Netherlands, 3Leiden University Medical Centre, Portela Loures, Portugal, 4Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 6Amsterdam University Medical Center, Meerssen, Netherlands, 7Leiden University Medical Center, Leiden, Netherlands, 8Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 9Leiden University Medical Center & King's College London, London, United Kingdom

    Background/Purpose: Since the 2016 recommendations for axial spondyloarthritis (axSpA) management, new evidence emerged regarding axSpA treatment. The aim of this work was to update the…
  • Abstract Number: 1033 • ACR Convergence 2022

    Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort

    Cosimo Cigolini1, Federico Fattorini1, Linda Carli2, Andrea Delle Sedie3, Marta Mosca2 and Gabriele Marchetti4, 1Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, Italy, 3University of Pisa, Pisa, Pisa, Italy, 4University of Pisa, Pisa, Toscana, Italy

    Background/Purpose: Spondyloarthropathies (SpA) are chronic inflammatory arthritides, characterized by both peripheral and axial skeletal involvement and some typical extra-articular marks; they tend to associate with…
  • Abstract Number: 1612 • ACR Convergence 2022

    Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk

    Lihi Eder1, Ker-Ai Lee2, Vinod Chandran3, Jessica Widdifield4, Aaron Drucker4, Christopher Ritchlin5, Cheryl F Rosen4, Richard Cook2 and Dafna Gladman6, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 6Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada

    Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
  • Abstract Number: 0416 • ACR Convergence 2022

    Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis

    Casper Webers1, Augusta Ortolan2, Alexandre Sepriano3, Louise Falzon4, Xenofon Baraliakos5, Robert Landewé6, Sofia Ramiro7, Désirée van der Heijde8 and Elena Nikiphorou9, 1Maastricht University Medical Centre, Maastricht, Netherlands, 2University of Padova/Leiden University Medical Center, Padova, Italy, 3Leiden University Medical Centre, Portela Loures, Portugal, 4Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 6Amsterdam University Medical Center, Meerssen, Netherlands, 7Leiden University Medical Center, Leiden, Netherlands, 8Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 9Leiden University Medical Center & King's College London, London, United Kingdom

    Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…
  • Abstract Number: 1035 • ACR Convergence 2022

    Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies

    Philip J Mease1, William Tillett2, Sarah Ohrndorf3, Michelle Perate4, Mary Medysky5, Miriam Zimmermann6, May Shawi7, Emmanouil Rampakakis8, Paul Bird9, Alen Zabotti10, Atul Deodhar11 and Dafna Gladman12, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Janssen Scientific Affairs, LLC, Seattle, WA, 6Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9University of New South Wales, Sydney, Australia, 10Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, 11Oregon Health & Science University, Portland, OR, USA, Portland, OR, 12Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada

    Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…
  • Abstract Number: 1768 • ACR Convergence 2022

    Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study

    Sanjana Tarannum1, Jessica Widdifield1, C. Fangyun Wang2, Sindhu R. Johnson3, Paula Rochon1 and Lihi Eder4, 1University of Toronto, Toronto, ON, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…
  • Abstract Number: 0796 • ACR Convergence 2022

    SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?

    Carla Goncalves Schahin Saad1, Matheus SR Silva2, PERCIVAL SAMPAIO-BARROS1, Julio Moraes3, Claudia G Schainberg2, Celio Roberto goncalves1, Andrea Shimabuco1, Nadia Aikawa1, Emily Figueiredo Neves Yuki1, Sandra Gofinet Pasoto4, Leonard VK Kupa2, Renato K Aoyama2, Carlo Araujo1, Clovis A. Silva5, ana Medeiros6 and Eloisa Silva Dutra de Oliveira Bonfa4, 1Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo, São Paulo, 3Faculdade de Medicina da Universidade de Sao Paulo, Jundiai, Brazil, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 6Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil

    Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…
  • Abstract Number: 1037 • ACR Convergence 2022

    Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies

    Xenofon Baraliakos1, Dafna Gladman2, Soumya Chakravarty3, Cinty Gong4, May Shawi5, Emmanouil Rampakakis6, Kishimoto Mitsumasa7, Enrique R Soriano8 and Philip J Mease9, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only…
  • Abstract Number: 2108 • ACR Convergence 2022

    Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA

    Stefan Siebert1, Georg Schett2, Siba P. Raychaudhuri3, Monica Guma4, Warner Chen5, Sheng Gao5, Soumya Chakravarty6, May Shawi7 and Proton Rahman8, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Universitätsklinikum Erlangen, Erlangen, Germany, 3Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, 4Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, 5Janssen Research and Development, LLC, Spring House, PA, 6Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Memorial University, St. John's, NL, Canada

    Background/Purpose: The IL-23p19 inhibitor guselkumab has shown robust efficacy vs placebo (PBO) in the phase 3 DISCOVER-1 and DISCOVER-2 studies of adults with active PsA,1,2…
  • Abstract Number: 0800 • ACR Convergence 2022

    Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications

    Alina Kifayat1, amy Wasserman2, Kirk Sperber1, Deana Nes3, Paul Arnaboldi4 and Julia Ash5, 1New York Medical College at Westchester Medical Center, Valhalla, NY, 2New York Medical College at Westchester Medical Center, Armonk, NY, 3Bergen Medical Associates, Ridgewood, NJ, 4New York Medical College, Valhalla, NY, 5New York Medical College at Westchester Medical Center, Dobbs Ferry, NY

    Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a…
  • Abstract Number: 1041 • ACR Convergence 2022

    Tofacitinib in Refractory Uveitis – an Observational Study

    Nikhil Gupta1 and Deepankur Mahajan2, 1Centre for Arthritis and Rheumatological diseases in Delhi, New Delhi, India, 2Mahajan Eye Centre, New Delhi, India

    Background/Purpose: To evaluate the effect of generic tofacitinib in refractory uveitis patients.Methods: It was a prospective observational study of 23 patients of refractory anterior uveitis.…
  • Abstract Number: 2109 • ACR Convergence 2022

    Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Arthur Kavanaugh1, Gordon Lam2, Lai-shan Tam3, Natalie Shiff4, Youngja Lee5, Ana-Maria Bravo Perdomo6, May Shawi7, Elizabeth Hsia8, Emmanouil Rampakakis9 and Carlos Enrique Toro Gutiérrez10, 1University of California San Diego, La Jolla, CA, 2Arthritis and Osteoporosis Consultants of the Carolinas; Clinical Affiliate, Atrium Health and the Wake Forest School of Medicine, Cornelius, NC, 3The Chinese University of Hong Kong, Hong Kong, China, 4Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, 5Immunology Medical Affairs, Janssen Asia Pacific, Yongsan-gu, Seoul, Republic of Korea, 6Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Research and Development, LLC; University of Pennsylvania School of Medicine, Kennett Square, PA, 9McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 10Internal Medicine and Rheumatology, Reference Center for Osteoporosis, Rheumatology & Dermatology. Pontificia Javeriana University, Calí, Colombia

    Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences